Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.

about

Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants.Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users.

P2860

Q49647319-ABAFAC7E-9FDC-41C3-9DDD-0B7B65979EEF Q52604641-FAAD7DFE-456A-4C15-8D03-4B4633ED8113

P2860

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.

Item

http://www.wikidata.org/entity/Q38602280

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Adherence to Rivaroxaban, Dabi ...... n Update Using 2013-2014 Data.

@en

type

Item

label

Adherence to Rivaroxaban, Dabi ...... n Update Using 2013-2014 Data.

@en

prefLabel

Adherence to Rivaroxaban, Dabi ...... n Update Using 2013-2014 Data.

@en

P1476

Adherence to Rivaroxaban, Dabi ...... n Update Using 2013-2014 Data.

@en

P2093

Anand R Shewale

http://www.w3.org/2001/XMLSchema#string

Jeffery C Talbert

http://www.w3.org/2001/XMLSchema#string

Joshua D Brown

http://www.w3.org/2001/XMLSchema#string

P2860

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

Administrative data based patient safety research: a critical review.

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.

Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors.

Edoxaban (Savaysa): A Factor Xa Inhibitor.

Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.

Warfarin discontinuation after starting warfarin for atrial fibrillation.

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.

P304

958-967

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18553/JMCP.2017.23.9.958

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28854077

http://www.w3.org/2001/XMLSchema#string

P932

5747360

http://www.w3.org/2001/XMLSchema#string

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.

about

P2860

P2860

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932